Food safety is an unsolved problem with an estimated 48 million foodborne illnesses occurring each year and costing over $50 billion.
PURE Bioscience is revolutionizing food safety with their heavily patented “SDC” and is positioned to become a leader in the food industry.
SDC has already been tested in several large restaurant chains and the results were significantly superior to all other methods. SDC is a powerful and extremely effective antimicrobial but it is safe to humans and has been granted the EPA’s safest product classification of a category IV.
LARGE RESTAURANT CHAINS are placing reorders that are expected to continue to increase to very sizeable numbers. PURE believes this is a 1.5 billion dollar market and SDC is far ahead of the competition.
Based on meetings with the USDA and the FDA, FOOD PROCESSORS are expected to be using SDC in 2015 to decontaminate produce and meat. SDC will also extend shelf life as well as reduce manufacturers costs. PURE believes this is billion-dollar market.
No other product can do what SDC does and do it safely.
SDC will dominate antimicrobials in hospitals, schools, homes, offices, markets, public places, cruise ships, airplanes, trains, personal products like soaps and everywhere the public gathers. Antimicrobial market for disease protection such as influenza, MRSA, etc. is another multi-billion dollar market
SDC is perfectly safe and it continues to kill dangerous pathogens for 24 hours EVEN AFTER IT DRIES.
PURE Bioscience is on the verge of delivering very large and fast growing revenues beginning this year and shares are trading between $1.10 and $1.20 with a very small market cap of $32 million.
All this information can be confirmed on YAHOO FINANCE under “PURE”
PURE is a Strong Buy and Hold
Sentiment: Strong Buy
$2.75+ coming on June 2 when GTXI presents their positive top-line results for their successful phase II trial for their Metastatic Breast Cancer drug Enobosarm 9 mg. The phase II trial met its primary endpoints early but almost nobody knows because official data and news has not been released to date per the ASCO agreement that it be presented at ASCO first. This is obviously still WAY off the radar and a ROCK BOTTOM STEAL hovering near its 52-week low. 80% insider owned means the TINY 20M float will move this one big and fast on this news. Pound for pound, this is the best play of ASCO 2014 BY FAR especially with all the other multiple near-term positive catalysts they have that will further back the stock up throughout the rest of 2014 into 2015.
Read this recent Seeking Alpha article below and you will see why GTXI will go to $2.75+ on June 2, 2014:
Pitt Hyde & Mason Hawkins Buy 50% Stake In GTx Ahead Of Phase II Results
Apr. 29, 2014 8:40 AM ET
GTXI has recently seen extraordinary insider buying and outside investment of $38 million.
Investors Pitt Hyde and Mason Hawkins have a successful track record of identifying undervalued companies poised for growth.
New investments in GTXI coincide with imminent catalyst of the release of Phase II trial results for metastatic cancer drug, Enobosarm.
Based on recent, positive Phase II trial results for other cancer drugs in sector, the average near-term gain is 109% post results release.
Pitt Hyde & Mason Hawkins Take Over 50% Stake in GTx Ahead of Phase II Results
In the recent, severe sell-off in biotech stocks, speculative investors are looking for bargains in the sector and signs of a bottom. With so many stocks suffering, it is very hard to navigate the many choices and pick which companies are buys at today's prices. The average retail investor does not have the time to do hours of research on hundreds of companies in their quest to find undervalued gems.
If you find yourself in that situation, perhaps this article will provide you with a specific, actionable investment idea. Opportunistic investors can gain insights into the right time and price to buy a stock by looking at what top investment pros and insiders ("smart money") are doing in a particular stock or sector.
For purposes of this article, I have found an attractive investment situation in a depressed stock where two key clues point to likely, near-term investment gains for those paying attention. In this case, the "smart money" is buying millions of shares and there is a positive, short-term catalyst clearly being telegraphed by management to occur very soon.
That company is GTx Inc. (GTXI), a San Diego biopharmaceutical company, engaging in the discovery, development, and commercialization of small molecules for the treatment of cancer, cancer supportive care, and other serious medical conditions. The company's stock now sits at $1.32 (near the 52-week low of $1.26) after a steep drop from $7.24 over the last year due to an unsuccessful Phase III trial reported in August 2013.
Additionally, with the resignation of the CEO Michael Steiner earlier this month (replaced by president and COO Marc Hanover), many have left the stock and company for dead. But those who have written off GTx may be missing an incredible opportunity to buy when the stock has finally bottomed based on insider buying and catalysts on the horizon.
Recent Insider Buys at 25% Premium to April 28 Closing Price
On March 6, two significant investors profiled below, J.R. "Pitt" Hyde, III and O. Mason Hawkins, participated in a private placement of GTx common stock and purchased 11,976,048 shares of GTXI at $1.78/share. This purchase included warrants for each investor to purchase an additional 5,089,821 shares (10,179,642 total shares) at $1.67/share. Once the warrants are fully exercised, these two investors will have acquired 22,155,690 share of GTXI at an average price of $1.73, an investment of over $38 million.
J.R. "Pitt" Hyde, III
O. Mason Hawkins*
GTXI Common Stock Purchase
GTXI Common Stock Warrants
*as principal Pyramid Peak Foundation donor
**weighted average price
With these extraordinary investments in GTXI, these two investors would now own over 50% of the company broken down as follows:
GTXI Shares Owned*
% of Shares Outstanding
J.R. "Pitt" Hyde, III
O. Mason Hawkins**
*assumes the exercise of $1.67 warrants
**as principal Pyramid Peak Foundation donor
To better understand the significance of these buys, we must shed some light on the investors involved.
J.R. "Pitt" Hyde: Insider Buyer
Because of his position as the founder & chairman of GTx and his incredible record as founder of AutoZone (AZO), Pitt Hyde's recent $19 million investment in GTx is very notable. This additional stake in GTx brings Hyde's ownership to 36.9% of the company. According to John Pontius, Hyde's money manager, Hyde's investment in GTx is "by a wide measure, the largest single investment he has made" since 1996.
Billionaire Pitt Hyde began to amass his fortune when he opened up his first auto parts store in Forest City, Arkansas in 1979. Now with 5,210 stores and estimated annual sales (2014) of $9.5 billion, AutoZone is the nation's largest auto parts retailer.
Similar to how he built AutoZone into a powerhouse, Hyde has taken an active role in his investment and senior leadership position at GTx. As chairman of the GTx Board of Directors, he is the principal architect of the company and the primary advisor to senior management on all matters of strategic importance.
While some may have seen the recent resignation of GTx CEO Michael Steiner as a negative, I completely trust Hyde's judgment in GTx personnel decisions and have confidence in the transition to Marc Hanover as the interim CEO (and I believe permanent soon) going forward. After all, Hanover was a fellow co-founder of the company with Hyde and he has been with GTx since its inception in 1997.
O. Mason Hawkins: Guru Buyer
Because of his investment guru status, extraordinary record in the investment business and his winning investment philosophy, Mason Hawkins' over $19 million investment in GTx Inc. (via Pyramid Peak Foundation) is also extremely notable.
Billionaire Mason Hawkins is the legendary founder & chairman of Southeastern Asset Management, Inc. His firm manages about $32 billion for endowments, foundations, and public and private retirement accounts. Hawkins is legendary because he has returned positive returns to his investors for the last 36 years.
As a value investor, Hawkins has specialized in patience and waiting for extremely discounted situations before investing in a company. In his most recent 2014 letter to shareholders, he explains his strategy this way,
"A broad market pullback could provide our next qualifiers. We are not market prognosticators, but few markets around the globe can claim undervaluation, and many have pockets of overvaluation. In the event of a correction, short-term performance is likely to decline. Our long-term results, however, will benefit from a lower P/V as we are armed with a vetted wish list of businesses and ample cash to be liquidity providers when new opportunities or existing names are offered at less than 60% of our appraisals. Additionally, lower prices will allow management teams at our current holdings to use their balance sheet strength to execute repurchases at deeper discounts that build values per share more rapidly."
Additionally, Hawkins has a philanthropic wing to his empire. In 2011, Mr. Hawkins established the Alzar Foundation with an initial gift of $41,000,000. Hawkins' company, Southeastern Asset Management, added $750,000 in initial funding. This Alzar Foundation is a Memphis-based charitable foundation established according to Hawkins to help "all our children have the finest education possible and to give women resources to better manage their lives and to support their families."
In its 2011 reporting period, the Alzar Foundation made charitable gifts totaling $85,000 to the following organizations: Kings Daughters and Sons ($25,000); Birdsong Nature Center ($10,000); Playhouse on the Square ($50,000).
Shortly thereafter in February 2012, the Alzar Foundation officially changed their name to become The Pyramid Peak Foundation. The Pyramid Peak Foundation performs no direct charitable activity, although it makes grants to existing charitable organizations to achieve their missions. Its sole gift in 2012 was a grant to the Community Foundation of Greater Memphis for $24,000,000.
Pyramid Peak Foundation grew dramatically by $348,313,409 in their 2012 reporting period to an asset base of $377,315,164, a nine-fold increase from the Alzar Foundation's modest beginnings of $41,750,000. This increase was due to the 2012 gifts to Pyramid Peak by Mason Hawkins, his daughters (Sidney & Katherine), and his company (Southeastern Asset) as follows:
2012 Gifts to The Pyramid Peak Foundation
O. Mason Hawkins
Katherine D. Hawkins
Longleaf Partners Fund Shares*
Sidney H. Gargiulo
Longleaf Partners Fund Shares*
Southeastern Asset Management, Inc.
*includes shares in Longleaf Partners Small-Cap, International, and Partners Fund
According to The Pyramid Peak Foundation's latest 990 form, Mason Hawkins' $160,000,000 cash gift was invested and managed for the foundation by Covey Capital Advisors in Atlanta, Georgia. One could assume that Covey Capital Advisors was chosen to manage the money because Hawkins' daughter, Sidney Hawkins Gargiulo is a partner at the wealth management firm.
Just 54 days ago on March 6, 2014, Mason Hawkins and Pyramid Peak Foundation reported a 13.8% stake (11,077,845 shares) in GTx. The common shares were purchased at $1.78, or 25% more than the April 28th closing price of $1.32.
Now to understand the timing of the Hawkins and Hyde buys, we must shed some light on what these investors expect to happen in the short term.
Near-Term Catalyst: Phase II Clinical Trial Results (Enobosarm for Treatment of Metastatic Breast Cancer)
There are surely many reasons why Hyde and Hawkins increased their positions in GTx in Q1 2014 to now own over 50% of the company. I suspect the timing of their buys has a lot to do with the release of Phase II trial results using promising drug Enobosarm for the treatment of metastatic breast cancer. If results are positive, this upcoming catalyst will likely be followed by a dramatic increase in share price according to an analysis of recent, positive Phase II cancer drug results as follows:
Date of Phase II Results
Share Price/ Pre-Results
Share Price Peak/ Post Results
Peak Gain %
GTx is currently conducting a Phase II open label study evaluating 9 milligram doses of Enobasarm for the treatment of estrogen receptor positive and androgen receptor positive metastatic breast cancer in women. The study is fully enrolled with 22 post-menopausal women with actively progressing breast cancer. The primary endpoint is a clinical benefit response after six months of Enbosarm 9 milligrams.
According to GTx's March 3, 2014, earnings conference call, the company "expects to meet the pre-specified goal of demonstrating at least three clinical benefit responses in a minimum of 14 patients." Management continued its bullish forecast by saying, "since we now anticipate that study will be successful, we also plan to meet with our key opinion leaders to determine how best to move forward in the clinical development of Enobasarm."
The data is expected late in second quarter of 2014. If the results are positive and GTx's share price reacts similarly to other Phase II trials listed above, the share price could rise as much as 109% to $2.75/share in very short order.
At a time when the biotech sector is out of favor and being sold off indiscriminately, GTx presents an interesting investment opportunity to buy shares alongside and at a 25% discount to a founding insider (Pitt Hyde) and one of the most highly respected value investors (Mason Hawkins) in the country.
If GTx gets the positive Phase II results for Enobosarm for the indication of breast cancer as management is publicly forecasting, the short-term increase in share price could match those seen in the sector for other cancer drugs bringing shareholders a healthy gain of over 100%.
Sentiment: Strong Buy
Millennium Healthcare (MHCC) recently announced newly SIGNED contracts with ACO’s IPA’s and MSO’s to provide exclusive, state-of-the-art, non-invasive cardiovascular and cancer diagnostics to 1,300 locations that will escalate Millennium’s current revenues of $2 million per year to over $300 million per year.
Millennium’s cardiovascular and cancer diagnostics are currently being rolled out and delivered to the physician’s offices and revenues will begin rapid growth in only a few months that will be reported by the 2014 year end and beyond.
This first 1,300 of 35,000 primary care offices have recently signed up and the rest are lining up to sign up with Millennium because:
• Millennium’s program increases physician’s revenues dramatically
• Millennium’s diagnostics are fully paid by Medicare and are free to patients
• Millennium’s diagnostics appeal to patients because they are life-saving, fast, painless and highly accurate
• Millennium’s diagnostics are exclusive from Millennium only
• The physician pays no up front capital costs
Millennium shares are selling at under $1.00.
Millennium’s market cap is under $40 million today.
What will this growth do to the price of their shares?
What is the potential for return on investment?
The reason shares are undervalued is that the company has no Investment Banker and no visibility.
Sentiment: Strong Buy